Targeting the Estrogen Receptor (ER) for the Treatment of Breast Cancer: Recent Advances and Challenges
University of Michigan Library · 2023-01-01
DOI: 10.7302/7864 ↗At a glance
Journal article in University of Michigan Library, published on 2023-01-01. Written by Rohan Kalyan Rej and 5 co-authors.
Abstract (original language)
Estrogen receptor alpha (ERα) is a well-established therapeutic target for the treatment of ER-positive (ER+) breast cancers. Despite the tremendous successes achieved by tamoxifen, a selective estrogen receptor modulator, and aromatase inhibitors (AIs), resistance to these therapies is a major clinical problem. Therefore, induced protein degradation and covalent inhibition have been pursued as new therapeutic approaches to target ERα. This review summarizes recent progress in the discovery and development of oral selective ER degraders (SERDs), CERANs (complete estrogen receptor antagonists), SERCAs (selective estrogen receptor covalent antagonists), and PROTAC (proteolysis targeting chimera) ER degraders. We focus on those compounds which have been advanced into clinical development
Subjects
Cite
APA
Rej, R. K., II, T., Eugene, J., Acharyya, R. K., Rae, J. M., & Wang, S. (2023). Targeting the Estrogen Receptor (ER) for the Treatment of Breast Cancer: Recent Advances and Challenges. University of Michigan Library. https://doi.org/10.7302/7864
Vancouver
Rej RK, II T, Eugene J, Acharyya RK, Rae JM, Wang S. Targeting the Estrogen Receptor (ER) for the Treatment of Breast Cancer: Recent Advances and Challenges. University of Michigan Library. 2023. doi:10.7302/7864
BibTeX
@article{Rej2023,
author = {Rej, Rohan Kalyan and II, Thomas and Eugene, Junius and Acharyya, Ranjan Kumar and Rae, James Michael and Wang, Shaomeng},
title = {Targeting the Estrogen Receptor (ER) for the Treatment of Breast Cancer: Recent Advances and Challenges},
journal = {University of Michigan Library},
year = {2023},
doi = {10.7302/7864}
}
EUVIMED